Drug Profile
MB 311
Alternative Names: MB311Latest Information Update: 01 Mar 2018
Price :
$50
*
At a glance
- Originator Meridian Biopharmaceuticals
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 01 Mar 2018 MB 311 is available for licensing as of 01 Mar 2018. http://www.meridian-biopharm.at/
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in Austria and Germany (Parenteral)
- 04 Jun 2015 MB 311 is still in phase I trials for Cancer in Austria and Germany